Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization

[1]  P. Austin,et al.  Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.

[2]  E. van Nood,et al.  Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: primary, contributing, or incidental COVID-19 , 2022, International Journal of Infectious Diseases.

[3]  J. L. Bernal,et al.  Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.

[4]  D. Cummings,et al.  Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant , 2022, medRxiv.

[5]  William F. Fadel,et al.  Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[6]  Manish M Patel,et al.  BNT162b2 Protection against the Omicron Variant in Children and Adolescents , 2022, The New England journal of medicine.

[7]  E. Lau,et al.  Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong , 2022, medRxiv.

[8]  M. Exline,et al.  Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[9]  Gheyath K Nasrallah,et al.  Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.

[10]  T. Leino,et al.  High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron , 2022, BMC Infectious Diseases.

[11]  M. Exline,et al.  Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.

[12]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[13]  T. Pavlík,et al.  Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2 , 2022, medRxiv.

[14]  William F. Fadel,et al.  Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[15]  P. Noble,et al.  Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[16]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[17]  A. Sette,et al.  T cell responses to SARS-CoV-2 spike cross-recognize Omicron , 2022, Nature.

[18]  William F. Fadel,et al.  Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[19]  Y. Young-Xu.  Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans , 2022, medRxiv.

[20]  M. Paleker,et al.  Change in profile of COVID-19 deaths in Western Cape Province, South Africa, during the fourth wave. , 2022, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[21]  M. Mendelson,et al.  Outcomes of laboratory‐confirmed SARS‐CoV‐2 infection in the Omicron‐driven fourth wave compared with previous waves in the Western Cape Province, South Africa , 2022, medRxiv.

[22]  M. Lipsitch,et al.  Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California , 2022, medRxiv.

[23]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.

[24]  Colin Simpson,et al.  Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and Scotland , 2022, SSRN Electronic Journal.

[25]  J. McLaughlin,et al.  BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design , 2022, SSRN Electronic Journal.

[26]  L. Bekker,et al.  Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.

[27]  L. Bekker,et al.  Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study. , 2021, medRxiv.

[28]  A. Monto,et al.  Immune-mediated attenuation of influenza illness after infection: opportunities and challenges. , 2021, The Lancet. Microbe.

[29]  L. Rosella,et al.  Acute Myocardial Infarction after Laboratory‐Confirmed Influenza Infection , 2018, The New England journal of medicine.

[30]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[31]  M. Halloran,et al.  Design and interpretation of vaccine field studies. , 1999, Epidemiologic reviews.